Navigation Links
Leading worldwide cause of cardiovascular disease may be modified by diet
Date:7/8/2008

Nashville, Tenn. July 7, 2008 A new article indicates that an increased intake in minerals such as potassium, and possibly magnesium and calcium by dietary means may reduce the risk of high blood pressure and decrease blood pressure in people with hypertension. A high intake of these minerals in the diet may also reduce the risk of coronary heart disease and stroke. These findings are published in a supplement appearing with the July issue of The Journal of Clinical Hypertension.

Potassium, specifically, has been hypothesized as one reason for the low cardiovascular disease rates in vegetarians, as well as in populations consuming primitive diets (generous in potassium and low in sodium). In isolated societies consuming diets high in fruits and vegetables, hypertension affects only 1 percent of the population, whereas in industrialized countries which consume diets high in processed foods and large amounts of dietary sodium, 1 in 3 persons have hypertension. Americans consume double the sodium and about half of the potassium that is recommended by current guidelines.

According to the paper, if Americans were able to increase their potassium intake, the number of adults with known hypertension with blood pressure levels higher than 140/90 mm Hg might decrease by more than 10 percent and increase life expectancy. Similar studies show that diets high in magnesium (at least 500 to 1,000 mg/d) and calcium (more than 800 mg/d) may also be associated with both a decrease in blood pressure and risk of developing hypertension. Data regarding these minerals, however, are not definitive.

"If we were to achieve the correct potassium/sodium ratio through dietary means, there would be less hypertension and cardiovascular disease in the population as a whole," says Mark C. Houston, M.D., author of the study.

Diets that emphasize fruits, vegetables and low-fat dairy products, including the landmark Dietary Approaches to Stop Hypertension (DASH) trial, have been advocated by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the American Heart Association, the European Society of Hypertension, the World Health Organization and the British Hypertension Society.

Hypertension is the leading cause of cardiovascular disease, affecting approximately 1 billion individuals worldwide and is the most common reason for visits to physician's offices and the primary reason for prescription drug use.

More than 70 million Americans, or nearly 1-in-3 adults, are estimated to have hypertension, but fewer than 50 percent achieve blood pressure control. Nearly 70 million more adults have high-normal or pre-hypertensive blood pressure levels of 120/80 mm Hg to 130/85 mm Hg, and 90 percent of adults will probably develop hypertension by age 65. Poor blood pressure control is a major challenge for patients with diabetes and chronic kidney disease. Despite major advances in the prevention and treatment of hypertension over the past decades, with a decrease of more than 60 percent in hypertension-related strokes, hypertension remains an important public health challenge.


'/>"/>

Contact: Bethany Carland
bcarland@wiley.com
781-388-8509
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
4. Leading-edge body sensor could help produce sporting champions
5. Hospital Quality Info on Web Can Be Misleading
6. AT&T Establishes New Network Services for Leading Medical Liability Insurer
7. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
10. Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert
11. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... , ... LARKR™ , an innovative new smartphone app providing on-demand talk ... to join its online treatment platform. , Launching in just a few days, ... number of people in need nationwide, and to supplement their traditional practices. Joining this ...
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a protocol ... that pledges to solve many catastrophic issues within funding campaigns. KICKICO developers are testing ... notion of crowdfunding - the raising of funds through the power of many - ...
(Date:6/25/2017)... ... , ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows ... 2 contains 60 different color-grade presets, giving editors multiple options for adding different color ... out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any ...
(Date:6/25/2017)... ... 2017 , ... Republicans in the United States Senate on Thursday released their ... Reconciliation Act. It differs significantly from the American Health Care Act, which the House ... or the House will have to take up the Senate version as-is, if it ...
(Date:6/25/2017)... ... ... CareSet Labs released the Root NPI Graph today at the 2017 Academy ... of the Doctor Referral teaming dataset commonly available from Medicare. , Originally created through ... “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by Trotter, the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology: